register

News & Trends - Medical Technology

Respiri to launch remote patient monitoring asthma trial in Australia

Health Industry Hub | March 31, 2021 |
[Total: 1    Average: 5/5]

MedTech News: Respiri is following up on its milestone medical device approval in the United States with a pilot telehealth trial in Australia that could serve as the basis for an American launch model.

Respiri is teaming with leading Sydney-based respiratory physician Dr Kevin Chan to provide a world-class telehealth service for patients with moderate to severe persistent asthma using the company’s wheezo wheeze-detecting device.

Patients will pay a premium monthly Product as a Service fee to access the programme and have Dr Chan and Resprii’s Connected Care Nurse team regularly review their data.

“I have many patients come and see me, describing their wheeze and other respiratory symptoms that happened weeks prior, which does not paint an accurate or complete picture of the patient’s respiratory condition,” Dr Chan says.

Leadership Management Qualities - J&J's Managing Director Susan Martin talks courage, compassion and communication on International Women’s Day

“Through remote digital monitoring and Connected Care consults, I expect to be in a much better position to understand the patient’s progress on a day-to-day basis. This is particularly important for patients with poor asthma control.”

Dr Chan says asthma is one of the most common conditions he treats at his practices. He’s based at Campbelltown Hospital and Sydney Adventist Hospital, Wahroonga.

The programme will also form the basis for the patient model Respiri intends to launch in the United States, taking advantage of Remote Patient Monitoring Current Procedural Terminology (CPT) billing codes under which Respiri or its partners can charge US doctors monthly Product as a Service fees of $US30 to $US40 per patient each month.

“This program represents a fantastic opportunity to trial wheezo with PaaS fee-paying patients in a clinical setting and will allow us to use real-world data to establish a scalable patient pathway that aims to improve the lives of asthma sufferers across Australia,” says Respiri chief executive Marjan Mikel.

“And very importantly, it will provide us with the basis of the patient model and programme for the US prescription/reimbursement market.”

The programme will be launched in April. Respiri plans to scale it to include other respiratory physicians and also create a potential corporate health respiratory offering for other employers and companies.

Asthma costs Australia $28 billion a year in healthcare costs and lost productivity. Respiri’s handheld wheezo device, which connects to smartphones via Bluetooth, could be a game-changer in helping asthma sufferers better manage their disease.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Leadership & Management

Leadership Management Qualities - The power of being an authentic leader

The power of being an authentic leader

Health Industry Hub | April 21, 2021 |

Leadership & Management: Welcome to Health Industry Hub’s Women in Leadership Series – connecting, engaging and empowering women in the […]

More


Digital & Innovation

Healthcare Technology Digital Innovations - Data is the biggest challenge, and opportunity, for MedTech

Data is the biggest challenge, and opportunity, for MedTech

Health Industry Hub | April 21, 2021 |

Digital & Innovation: Medical technology is increasingly shaping the future of healthcare. The sector is also a growing part of […]

More


News & Trends - Medical Technology

MedTech News - Thermo Fisher acquisition to better serve its pharma and biotech clients

Thermo Fisher acquisition to better serve its pharma and biotech clients

Health Industry Hub | April 21, 2021 |

MedTech News: Thermo Fisher Scientific is buying clinical research services provider PPD for a hearty $17.4 billion, and that’s not its only acquisition this […]

More


News & Trends - Pharmaceuticals

Pharma News - First-in-class oncology drug candidate licensed by Aussie pharma

First-in-class oncology drug candidate licensed by Aussie pharma

Health Industry Hub | April 21, 2021 |

Pharma News: An Australian oncology-focused drug development company entered into a worldwide exclusive licensing agreement and a master services agreement […]

More